Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review

Department of Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
Journal of the American Academy of Dermatology (Impact Factor: 5). 11/2008; 59(6):1017-30. DOI: 10.1016/j.jaad.2008.07.042
Source: PubMed

ABSTRACT Ultraviolet (UV) A-1 phototherapy is now available for a variety of skin diseases. Increasingly since 1995, there have been investigations of the efficacy of UVA-1 (340-400 nm) therapy for sclerotic skin diseases. Most studies undertaken treated patients who had localized scleroderma, but UVA-1 phototherapy is currently also used for other sclerotic skin conditions.
We sought to assess the efficacy, biological effects, and side effects of UVA-1 in a variety of sclerotic skin diseases (localized scleroderma, eosinophilic fasciitis, chronic graft-versus-host disease, lichen sclerosus et atrophicus, scleredema adultorum, necrobiosis lipoidica, POEMS disease, pansclerotic porphyria cutanea tarda, and drug-induced scleroderma-like disorders).
The authors searched for publications dated between January 1996 and November 2007 in the computerized bibliographic database, PubMed. PubMed was searched using medical subject heading terms and open searches to retrieve the latest reports.
The evidence based on research concerning the effect of full-spectrum UVA (320-400 nm) and UVA-1 on these skin diseases is still growing, and appears promising. Up until now, good results are shown for all different doses (low, medium, and high) UVA-1 and UVA. There are insufficient data regarding use of high-dose UVA-1 and there are no comparative studies to make a clear assessment regarding the superiority of low-, medium-, or high-dose UVA-1 therapy. Although UVA-1 has various effects on, for instance, fibroblasts and inflammatory cells, the precise mode of action remains obscure. The main short-term side effects of UVA-1 therapy are erythema, pruritus, xerosis cutis, tanning, and recrudescence of herpes simplex infection. More studies are warranted to investigate the potential long-term risk of photoaging and skin cancer. Currently, UVA-1 is considered to be less carcinogenic than psoralen plus UVA (PUVA).
Because of the limited availability of randomized controlled trials and large cohort studies, it is difficult to draw firm conclusions on the long-term efficacy, optimum dose, and best treatment regimens for UVA-1 when administered to patients with sclerosing skin disorders.
Full-spectrum UVA and UVA-1 phototherapy seem effective in the treatment of sclerotic skin diseases based on data retrieved from the literature. UVA-1 treatment can shorten the active period of localized scleroderma and pseudoscleroderma and prevent further disease progression, including contractures. Further investigations will be needed to determine any additional biological effects of UVA-1. Although long-term side effects are not yet known, UVA-1 might develop into a promising beneficial and well-tolerated treatment in the therapeutic armamentarium for sclerotic skin diseases. Long-term studies in large groups of patients are clearly needed.

1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The chronic graft-versus-host-disease (GVHD) is the most frequent and serious complication of the allogenic bone marrow transplantation. We present a patient who was refractory to prednisone, cyclosporine A, mycophenolate mofetil, ultraviolet irradiation and psoralen (PUVA), and rituximab.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lichen sclerosus is a chronic skin condition that most commonly affects the anogenital skin of postmenopausal women. The aetiology of the condition is multifactorial. The most common presenting symptom is itching. Lichen sclerosus has a characteristic appearance. Diagnosis is made with vulvar biopsy. Treatment is important and the regimen most often includes topical corticosteroid ointments. Lifetime surveillance of the skin is imperative because of the increased risk of squamous cell carcinoma in patients with lichen sclerosus.
    Drugs & Aging 01/2009; 26(10):803-12. DOI:10.2165/11316820-000000000-00000 · 2.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Summary Localized scleroderma is a rare autoimmune disease with primary affection of the skin, and occasional involvement of the fat tissue, muscle, fascia, and bone. Depending on the clinical subtype, the spectrum of skin lesions ranges from singular plaque lesions to severe generalized or linear subtypes which may lead to movement restrictions and permanent disability. This German S1-guideline proposes a classification of localized scleroderma that, considering the extent and depth of fibrosis, distinguishes limited, generalized, linear, and deep forms of localized scleroderma, together with its associated subtypes. The guideline includes a description of the pathogenesis, of differential diagnoses, and particular aspects of juvenile localized scleroderma, as well as recommendations for histopathologic, serologic, and biometric diagnostic procedures. Based on studies of topical and systemic treatments as well as phototherapy for localized scleroderma published in international literature, a treatment algorithm was developed which takes account of the different subtypes and the extent of disease.
    Journal der Deutschen Dermatologischen Gesellschaft 01/2009; 7. DOI:10.1111/j.1610-0387.2009.07178_supp.x · 1.82 Impact Factor


Available from